ABSTRACT
The article considers possibilities and means of transition to personalized treatment of patients with tuberculosis conditioned by fast development and spreading of medicinal resistance of tuberculosis agent. The technical possibilities are demonstrated for realization of this approach and also necessity of information possessing in the field of evaluation of treatment effectiveness. Also, attention was paid to relationship ofpharmacogenetics and pharmacokinetics of wide spectrum of anti-tuberculosis medications, medicinal resistance of agent and genetic conditioning of development of side-effect negative reactions to chemotherapy.
Subject(s)
Antitubercular Agents , Drug Resistance, Bacterial , Pharmacogenetics/methods , Tuberculosis/diagnosis , Tuberculosis/drug therapy , HumansABSTRACT
Effective accumulation of binuclear dinitrosyl iron complexes with glutathione was shown after a subcutaneous para lymphatic injection of an aqueous solution of a dinitrosyl-iron complex into animal lung tissue at a single-dose of 2 micromoles per kilogram two times a day with a 2-h interval. Two hours later after the administration was repeated the concentration of these complexes was 16 micromoles per kilogram of tissue dropping down for the last two hours to 7 micromoles per kilogram of tissue. At one dose injection of binuclear dinitrosyl iron complexes with glutathione their concentration in 2 and 4 hours was two times lower than in the previous experiments. Presumably at the obtained concentration of dinitrosyl iron complexes a bactericidal effect in lungs can be observed against mycobacterium tuberculosis and rapidly proliferating lung tumors.
